Abstract 822: Netrin-1/UNC5B-TFF3 axis modulates cancer stem cells self-renewal and chemoresistance in metastatic colorectal cancer.

Abstract Purpose: Metastatic colorectal cancer (mCRC) exhibits poor outcomes due to recurrence and resistance to chemotherapy driven by cancer stem cells (CSCs). We investigated the role of the dependence receptor ligand netrin-1 and its receptor UNC5B in CSC self-renewal and evaluated therapeutic inhibition of netrin-1 using the anti-netrin-1 antibody NP137. Experimental Procedures: Patient-derived organoids (PDOs) from colorectal liver metastases were treated with recombinant netrin-1, NP137, or controls. Self-renewal was quantified by extreme limiting dilution assays. UNC5B was silenced by CRISPR/Cas9 to determine receptor the implication of this Netrin-1 receptor. Single-cell RNA-sequencing elucidated signaling pathways affected by NP137. In vivo efficacy of NP137 alone or combined with FOLFOX chemotherapy was tested in PDO-xenografted mice, and paired tumor biopsies from an mCRC patient enrolled in an NP137 clinical trial were analyzed by RNA-seq. Results: Netrin-1 enhanced CSC self-renewal and survival, effects abolished by NP137 or UNC5B knockout. NP137 treatment triggered CSC apoptosis, an effect reversed by caspase inhibition. Single-cell transcriptomics revealed that UNC5B-positive cells secreted trefoil factor 3 (TFF3), which acted paracrinally to maintain stemness gene expression (LGR5, SOX4, SMOC2, PROM1). NP137 suppressed TFF3 and stemness transcripts in both PDOs and a treated patient’s tumor. Blocking TFF3 dimerization phenocopied NP137 activity, confirming TFF3 as a critical downstream effector. FOLFOX exposure upregulated netrin-1 and UNC5B, and combination therapy (FOLFOX + NP137) significantly reduced self-renewal and tumor growth in mice while decreasing intratumoral TFF3. Conclusions: Netrin-1 sustains mCRC CSC self-renewal through an UNC5B-dependent, TFF3-mediated paracrine survival mechanism. Pharmacologic inhibition of netrin-1 with NP137 induces CSC apoptosis and enhances chemotherapy efficacy, identifying the netrin-1/UNC5B/TFF3 axis as a promising therapeutic target to overcome stemness-driven resistance in metastatic colorectal cancer. Citation Format: Morgan Brisset, Kristina Radkova, Andrea Paradisi, Lea Stephan, Robin Wagner, Cyril Degletagne, Fabien Luiggi, Lisa Frydman, Alexander Heriot, Corina Behrenbruch, Tamara Vu, Frédéric Hollande, Patrick Mehlen. Netrin-1/UNC5B-TFF3 axis modulates cancer stem cells self-renewal and chemoresistance in metastatic colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 822.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-822
Primary Topic
Axon Guidance and Neuronal Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 822: Netrin-1/UNC5B-TFF3 axis modulates cancer stem cells self-renewal and chemoresistance in metastatic colorectal cancer.

Cyril Dégletagne, Lea Stephan, Alexander G. Heriot, Corina Behrenbruch et al.
Cancer Research
Axon Guidance and Neuronal Signaling
article

Abstract 822: Netrin-1/UNC5B-TFF3 axis modulates cancer stem cells self-renewal and chemoresistance in metastatic colorectal cancer.

Cyril Dégletagne, Lea Stephan, Alexander G. Heriot, Corina Behrenbruch, Tamara M. Vu, Morgan Brisset, Frédéric Hollande, Kristina Radkova, Fabien Luiggi, Andrea Paradisi, Patrick Mehlen, Lisa Frydman, Robin Wagner
article en

Abstract

Abstract Purpose: Metastatic colorectal cancer (mCRC) exhibits poor outcomes due to recurrence and resistance to chemotherapy driven by cancer stem cells (CSCs). We investigated the role of the dependence receptor ligand netrin-1 and its receptor UNC5B in CSC self-renewal and evaluated therapeutic inhibition of netrin-1 using the anti-netrin-1 antibody NP137. Experimental Procedures: Patient-derived organoids (PDOs) from colorectal liver metastases were treated with recombinant netrin-1, NP137, or controls. Self-renewal was quantified by extreme limiting dilution assays. UNC5B was silenced by CRISPR/Cas9 to determine receptor the implication of this Netrin-1 receptor. Single-cell RNA-sequencing elucidated signaling pathways affected by NP137. In vivo efficacy of NP137 alone or combined with FOLFOX chemotherapy was tested in PDO-xenografted mice, and paired tumor biopsies from an mCRC patient enrolled in an NP137 clinical trial were analyzed by RNA-seq. Results: Netrin-1 enhanced CSC self-renewal and survival, effects abolished by NP137 or UNC5B knockout. NP137 treatment triggered CSC apoptosis, an effect reversed by caspase inhibition. Single-cell transcriptomics revealed that UNC5B-positive cells secreted trefoil factor 3 (TFF3), which acted paracrinally to maintain stemness gene expression (LGR5, SOX4, SMOC2, PROM1). NP137 suppressed TFF3 and stemness transcripts in both PDOs and a treated patient’s tumor. Blocking TFF3 dimerization phenocopied NP137 activity, confirming TFF3 as a critical downstream effector. FOLFOX exposure upregulated netrin-1 and UNC5B, and combination therapy (FOLFOX + NP137) significantly reduced self-renewal and tumor growth in mice while decreasing intratumoral TFF3. Conclusions: Netrin-1 sustains mCRC CSC self-renewal through an UNC5B-dependent, TFF3-mediated paracrine survival mechanism. Pharmacologic inhibition of netrin-1 with NP137 induces CSC apoptosis and enhances chemotherapy efficacy, identifying the netrin-1/UNC5B/TFF3 axis as a promising therapeutic target to overcome stemness-driven resistance in metastatic colorectal cancer. Citation Format: Morgan Brisset, Kristina Radkova, Andrea Paradisi, Lea Stephan, Robin Wagner, Cyril Degletagne, Fabien Luiggi, Lisa Frydman, Alexander Heriot, Corina Behrenbruch, Tamara Vu, Frédéric Hollande, Patrick Mehlen. Netrin-1/UNC5B-TFF3 axis modulates cancer stem cells self-renewal and chemoresistance in metastatic colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 822.

Cancer ResearchVol. 86(7_Supplement)
The University of Melbourne (AU), Peter MacCallum Cancer Centre (AU), Centre de Recherche en Cancérologie de Lyon (FR)
Good health and well-being
Openalex Percentile: Top 32%
Axon Guidance and Neuronal Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.